Why would this be the case? The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor Agonist to help obesity patients lose weight is already established. Not only that ...

The drug developer is testing apitegromab, an experimental therapy that targets the myostatin protein, alongside GLP-1 treatments ... from South Korean firm MOA Life Plus last year.

Roche plans to start a mid-stage trial this year combining the drug and its own GLP-1 weight-loss drug candidate ... and EL-32 - from South Korean firm MOA Life Plus last year.

Roche plans to start a mid-stage trial this year combining the drug and its own GLP-1 weight-loss drug candidate CT-388 ... targeting drugs - EL-22 and EL-32 - from South Korean firm MOA Life Plus ...

A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...

By screening people for eating disorders and disordered eating before these medications are prescribed, we can prevent unintended consequences.

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...